FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells.
FibroBiologics has raised $3.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
FibroBiologics's investors include Yorkville Advisors, The Global Emerging Markets Group.
FibroBiologics is headquartered in Houston, United States.
FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells.
FibroBiologics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"FibroBiologics — Funding & Investors." VCBacked, June 29, 2026, https://www.vcbacked.co/company/fibrobiologics. Accessed November 13, 2026.
VCBacked. (2026). FibroBiologics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/fibrobiologics
{{cite web |title=FibroBiologics — Funding & Investors |url=https://www.vcbacked.co/company/fibrobiologics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at FibroBiologics? Request a listing update